![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Final Results PROVIDE Study: Boceprevir in null-responders
|
|
|
Reported by Jules Levin
DDW 2013 May 18-21 Orlando Florida
J Vierling1, FA Helmond2, J Wahl2, W Deng2, JP Bronowicki3
1Baylor College of Medicine, Houston, TX, USA, 2Merck Sharp & Dohme Corp, Whitehouse Station, NJ, USA; 3University Henri Poincare of Nancy, Vandoeuvre-les-Nancy, France.
![EASL1.gif](../images/052113/052113-1/EASL1.gif)
![EASL2.gif](../images/052113/052113-1/EASL2.gif)
![EASL3.gif](../images/052113/052113-1/EASL3.gif)
![EASL4.gif](../images/052113/052113-1/EASL4.gif)
![EASL5.gif](../images/052113/052113-1/EASL5.gif)
![EASL6.gif](../images/052113/052113-1/EASL6.gif)
![EASL7.gif](../images/052113/052113-1/EASL7.gif)
![EASL8.gif](../images/052113/052113-1/EASL8.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|